Scalpels, beams, drugs, and dreams: Challenges of stage IIIA-N2 non-small-cell lung cancer

Journal of the National Cancer Institute

Volumn 99, Issue 6, 2007, Pages 415-418

  Johnson, David H ^a   Rusch, Valerie W ^b   Turrisi, Andrew T ^c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE; PACLITAXEL;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; EARLY DIAGNOSIS; EDITORIAL; ENDOSCOPIC ECHOGRAPHY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; METASTASIS; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; LUNG TUMOR; METHODOLOGY; NOTE; PATHOLOGY; REMISSION; SURVIVAL; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 34047274606     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk107     Document Type: Editorial

References (27)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
2. Robinson LA, Wagner HJr, Ruckdeschel JC. Treatment of stage IIIA non-small cell lung cancer. Chest 2003;123:202S-20S.
3. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
4. Douillard J-Y, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 2006;7:719-27.
5. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987;67:1037-49.
6. Goldstraw P. Selection of patients for surgery after induction chemotherapy for N2 non-small-cell lung cancer. J Clin Oncol 2006;24:3317-8.
7. Fritscher-Ravens A, Bohuslavizki KH, Brandt L, Bobrowski C, Lund C, Knofel WT, et al. Mediastinal lymph node involvement in potentially resectable lung cancer: Comparison of CT, positron emission tomography, and endoscopic ultrasonography with and without fine-needle aspiration. Chest 2003;123:442-51.
8. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-5.
9. Eberhardt WE, Albain KS, Pass H, Putnam JB, Gregor A, Assamura H, et al. Induction treatment before surgery for non-small cell lung cancer. Lung Cancer 2003;42 Suppl 1:S9-14.
10. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol 2005;23:3257-69.
11. van Meerbeeck JP, Kramer GWPM, Van Schil PEY, Legrand C, Smit EF, Schramel F, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-50.
12. Rusch VW. Mediastinoscopy: An endangered species? J Clin Oncol 2005; 23:8283-5.
13. Johnstone DW, Byhardt RW, Ettinger D, Scott CB. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002;54:365-9.
14. Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 2005;23:624s.
15. Martin J, Ginsberg RJ, Abolhoda A, Bains MS, Downey RJ, Korst RJ, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: The risks of right pneumonectomy. Ann Thorac Surg 2001;72: 1149-54.
16. Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005;23:3760-7.
17. Bentzen SM, Saunders MI, Dische S. From CHART to CHARTWEL in non-small cell lung cancer: Clinical radiobiological modelling of the expected change in outcome. Clin Oncol (R Coll Radiol) 2002;14: 372-81.
18. Van Zandwijk N, Smit EF, Kramer GWP, Schramel F, Gans S, Festen J, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000;18:2658-64.
19. O'Brien ME, Splinter T, Smit EF, Biesma B, Krzakowski M, Tjan-Heijnen VCG, et al. Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer - an EORTC phase II study (EORTC 08958). Eur J Cancer 2003;39:1416-22.
20. Biesma B, Manegold C, Smit HJ, Willems L, Legrand C, Passioukou A, et al. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: A phase II study of the European organization for research and treatment of cancer (EORTC 08984). Eur J Cancer 2006;42:1399-406.
21. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
22. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-41.
23. Silvestri GA, Handy J, Lackland D, Corley E, Reed CE. Specialists achieve better outcomes than generalists for lung cancer surgery. Chest 1998;114:675-80.
24. Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001;345:181-8.
25. Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006;3:e467.
26. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
27. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.